Skip to content

Study · Not a test of the peptide alone · 2018

8 results

Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.

Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E

Diabetes, obesity & metabolism31 Jul 2017Cited by 13 (Europe PMC)

PMID28643425 (opens in a new tab)PMCIDPMC5763397 (opens in a new tab)DOI10.1111/dom.13043 (opens in a new tab)PepBankPUB-28643425
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, IDegLira reduced HbA1c across all baseline HbA1c categories, by more than insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, the IDegLira combination lowered HbA1c more than insulin glargine at all starting HbA1c levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction across baseline HbA1c categories
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100.
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, IDegLira reduced HbA1c across all baseline fasting plasma glucose categories, by more than insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, the IDegLira combination lowered HbA1c more than insulin glargine at all starting fasting glucose levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction across baseline FPG categories
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100.
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, IDegLira reduced HbA1c across all BMI categories, by more than insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, the IDegLira combination lowered HbA1c more than insulin glargine at all body mass index levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction across BMI categories
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100.
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, IDegLira resulted in weight loss, whereas insulin glargine U100 resulted in weight gain, in all HbA1c, FPG and BMI categories.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, the IDegLira combination led to weight loss, while insulin glargine led to weight gain.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, hypoglycaemia rates were lower with IDegLira than with insulin glargine U100.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, low blood sugar happened less often with the IDegLira combination than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseHypoglycaemia rates
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    hypoglycaemia rates were lower for IDegLira vs IGlar U100.
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, more patients reached HbA1c below 7% with IDegLira (59%-87%) than with insulin glargine U100 (31%-66%) across baseline HbA1c categories.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, more people reached HbA1c below 7% with the IDegLira combination than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients reaching HbA1c below 7% by baseline HbA1c category
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%).
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, more patients reached HbA1c below 7% with IDegLira (71%-74%) than with insulin glargine U100 (40%-51%) across baseline fasting plasma glucose categories.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, more people reached HbA1c below 7% with the IDegLira combination than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients reaching HbA1c below 7% by baseline FPG category
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%).
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes uncontrolled on basal insulin, more patients reached HbA1c below 7% with IDegLira (71%-73%) than with insulin glargine U100 (40%-54%) across BMI categories.

    In plain wordsIn adults with type 2 diabetes uncontrolled on basal insulin, more people reached HbA1c below 7% with the IDegLira combination than with insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePatients reaching HbA1c below 7% by BMI category
    Study

    n: not reported in source

    Comparator
    Insulin glargine U100
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%).
    1 context sentence
    Summary · context
    This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; 2 ) and fasting plasma glucose (FPG;…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01952145

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 55720 Sept 2013 to 4 Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.